Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Ongoing, recruiting
Participants planned
592
Countries
8
Sites
26
Solid tumours with HER2 aberrations
Key facts
- Sponsor
- Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Neoplasms [C04]
- Trial duration
- 27 Jul 2021 → ongoing
- Decision date (initial)
- 2024-09-26
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2024-511246-39-00
- EudraCT number
- 2020-004563-47
- WHO UTN
- U1111-1312-5969
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Solid tumours with HER2 aberrations
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Boehringer Ingelheim International GmbH
- Sponsor organisation
- Boehringer Ingelheim International GmbH
- Address
- Binger Strasse 173
- City
- Ingelheim Am Rhein
- Postcode
- 55216
- Country
- Germany
Scientific contact point
- Organisation
- Boehringer Ingelheim International GmbH
- Contact name
- CT Disclosure & Data Transparency
Public contact point
- Organisation
- Boehringer Ingelheim International GmbH
- Contact name
- CT Disclosure & Data Transparency
Boehringer Ingelheim Espana S.A.
- Sponsor organisation
- Boehringer Ingelheim Espana S.A.
- Address
- Carrer Prat De La Riba 50, Sant Cugat Del Valles Sant Cugat Del Valles
- City
- Barcelona
- Postcode
- 08174
- Country
- Spain
Locations
8 EU/EEA countries · 26 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Belgium | Ongoing, recruiting | 2 | 1 |
| France | Ongoing, recruiting | 31 | 6 |
| Germany | Ongoing, recruiting | 20 | 5 |
| Italy | Ongoing, recruiting | 2 | 3 |
| Netherlands | Ongoing, recruiting | 71 | 2 |
| Portugal | Ongoing, recruiting | 1 | 2 |
| Spain | Ongoing, recruiting | 33 | 6 |
| Sweden | Ongoing, recruiting | 2 | 1 |
| Rest of world
Korea, Republic of, Australia, United States, United Kingdom, Japan, Israel, China, Singapore, Hong Kong
|
— | 430 | — |
Investigational sites
Institut Jules Bordet
Oncology department, Mijlenmeersstraat 90, 1070, Anderlecht
Institut Curie
Oncologie Médicale, 26 Rue D Ulm, 75005, Paris
Centre Hospitalier Regional De Marseille
Unité de Phase I Oncologie labélisée CLIP, 264 Rue Saint Pierre, 13005, Marseille
Institut Gustave Roussy
Service d’Onco-Pneumologie, 39 Rue Camille Desmoulins, 94805, Villejuif Cedex
Centre Leon Berard
Oncologie Médicale, 28 Rue Laennec, 69008, Lyon
Hospices Civils De Lyon
Plateforme de traitements oncologiques, 59 Boulevard Pinel, 69500, Bron
Centre Hospitalier Universitaire De Rennes
Unité d'Investigation Clinique, 2 Rue Henri Le Guilloux, 35000, Rennes
Universitaetsklinikum Augsburg
II. Medizinische Klinik, Stenglinstrasse 2, Kriegshaber, Augsburg
Pius-Hospital Oldenburg
Klinik für Hämatologie und Onkologie, Georgstrasse 12, Innenstadt, Oldenburg
Justus-Liebig-Universitaet Giessen
Universitätsklinikum Gießen und Marburg GmbH, Gaffkystrasse 5, 35392, Giessen
University Hospital Cologne AöR
Klinik I für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
Technische Universitaet Dresden
Medizinische Klinik und Poliklinik I, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Oncologia Medica, Strada Provinciale 142 Orba Km 3,95, 10060, Candiolo
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Sc Ematologia Oncologia, Via Mariano Semmola 52, 80131, Naples
Azienda Ospedaliero Universitaria Parma
U. O. di Oncologia Medica, Viale Antonio Gramsci 14, 43126, Parma
Leids Universitair Medisch Centrum (LUMC)
Longziekten, Albinusdreef 2, 2333 ZA, Leiden
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Klinische Farmacologie, Plesmanlaan 121, 1066 CX, Amsterdam
Hospital Cuf Descobertas S.A.
Serviço de Oncologia, Rua Mario Botas 1, 1998-018, Lisbon
Hospital CUF Porto S.A.
Serviço Pneumologia, Estrada Da Circunvalacao N 14341, 4100-180, Porto
Hospital General Universitario Gregorio Maranon
Thoracic Oncology, Head & Neck and Sarcoma Unit, Calle Del Doctor Esquerdo 46, 28007, Madrid
Hospital Clinico Universitario De Valencia
Servicio de Hematología y Oncología, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Virgen De La Victoria
UGC Oncología Intercentros, Calle Del Arroyo Teatinos S/N, 29010, Malaga
Hospital Universitario 12 De Octubre
Servicio de Oncología, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitari Vall D Hebron
Servicio de Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Institut Catala D'oncologia
Department of Medical Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Belgium | 2023-09-27 | 2024-01-22 | |||
| France | 2023-06-19 | 2023-06-21 | |||
| Germany | 2023-04-20 | 2023-06-13 | |||
| Italy | 2023-10-19 | 2023-12-01 | |||
| Netherlands | 2021-07-27 | 2021-08-20 | |||
| Portugal | 2023-09-25 | 2024-05-16 | |||
| Spain | 2023-05-05 | 2023-05-30 | |||
| Sweden | 2023-09-28 | 2023-10-19 |
Application history
9 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-09-03 | Spain | Acceptable with conditions 2024-09-25
|
2024-09-25 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2024-12-04 | Spain | Acceptable 2025-03-31
|
2025-03-31 |
| 3 | SUBSTANTIAL MODIFICATION | SM-2 | 2025-05-02 | Spain | Acceptable 2025-08-08
|
2025-08-08 |
| 4 | SUBSTANTIAL MODIFICATION | SM-4 | 2025-09-02 | Acceptable | 2025-09-18 | |
| 5 | SUBSTANTIAL MODIFICATION | SM-5 | 2025-09-02 | Spain | Acceptable | 2025-10-20 |
| 6 | SUBSTANTIAL MODIFICATION | SM-6 | 2025-09-02 | Acceptable | 2025-10-08 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-3 | 2025-09-03 | Acceptable | 2025-10-08 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-7 | 2025-11-19 | Spain | Acceptable 2026-01-29
|
2026-01-29 |
| 9 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2026-05-20 | Spain | Acceptable 2026-01-29
|
2026-05-20 |